<DOC>
	<DOCNO>NCT02962765</DOCNO>
	<brief_summary>Prospective , multinational , non-interventional post-authorisation study collect additional clinical data ensure consistency long-term outcome pre-authorisation clinical study ( 135 previously treat paediatric adult patient ) routine clinical practice . Besides aspect general product safety efficacy , focus immunogenicity , particularly inhibitor development . The diagnosis FVIII inhibitor base clinical observation confirm FVIII inhibitor test laboratory .</brief_summary>
	<brief_title>Non-interventional Post-authorisation Study Document Immunogenicity , Safety , Efficacy NUWIQ</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<criteria>Haemophilia A ( FVIII : C ≤ 2 % ) base medical history ; least 100 patient severe haemophilia A ( FVIII : C &lt; 1 % ) Male patient age Previous treatment FVIII concentrate 150 EDs Availability detail documentation ( patient diary , log book , etc . ) cover either last 50 EDs last 2 year per patient confirm treatment modality ( i.e. , prophylaxis , ondemand , recent surgery , immune tolerance induction ) Inhibitor negative ( &lt; 0.6 BU ) study entry confirm recovery test previous FVIII product inhibitor test central laboratory Immunocompetence ( CD4+ count &gt; 200/µL ) , HIVnegative , viral load &lt; 200 particles/µL &lt; 400,000 copies/mL Decision prescribe Humancl rhFVIII enrolment study Written inform consent patient patient 's parent legal guardian Patients treat investigational medicinal product ( IMP ) except FVIII IMP within 30 day prior Screening Visit patient plan undergo treatment IMP Humancl rhFVIII eligible enrolment study .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>